PH12020551580A1 - Piperidine compounds as covalent menin inhibitor-0s - Google Patents

Piperidine compounds as covalent menin inhibitor-0s

Info

Publication number
PH12020551580A1
PH12020551580A1 PH12020551580A PH12020551580A PH12020551580A1 PH 12020551580 A1 PH12020551580 A1 PH 12020551580A1 PH 12020551580 A PH12020551580 A PH 12020551580A PH 12020551580 A PH12020551580 A PH 12020551580A PH 12020551580 A1 PH12020551580 A1 PH 12020551580A1
Authority
PH
Philippines
Prior art keywords
covalent
piperidine compounds
menin inhibitor
menin
formula
Prior art date
Application number
PH12020551580A
Other languages
English (en)
Inventor
Shaomeng Wang
Shilin Xu
Angelo Aguilar
Liyue Huang
Jeanne Stuckey
Meng Zhang
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of PH12020551580A1 publication Critical patent/PH12020551580A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12020551580A 2018-03-30 2020-09-28 Piperidine compounds as covalent menin inhibitor-0s PH12020551580A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650777P 2018-03-30 2018-03-30
US201862740549P 2018-10-03 2018-10-03
PCT/US2019/024729 WO2019191526A1 (en) 2018-03-30 2019-03-29 Piperidine compounds as covalent menin inhibitors

Publications (1)

Publication Number Publication Date
PH12020551580A1 true PH12020551580A1 (en) 2021-09-13

Family

ID=68060814

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551580A PH12020551580A1 (en) 2018-03-30 2020-09-28 Piperidine compounds as covalent menin inhibitor-0s

Country Status (14)

Country Link
US (1) US20210115018A1 (cg-RX-API-DMAC10.html)
EP (1) EP3774731A4 (cg-RX-API-DMAC10.html)
JP (1) JP2021519785A (cg-RX-API-DMAC10.html)
KR (1) KR20200136958A (cg-RX-API-DMAC10.html)
CN (1) CN111936465A (cg-RX-API-DMAC10.html)
AU (1) AU2019243587A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020020059A2 (cg-RX-API-DMAC10.html)
CA (1) CA3093454A1 (cg-RX-API-DMAC10.html)
IL (1) IL277659A (cg-RX-API-DMAC10.html)
MX (1) MX2020010181A (cg-RX-API-DMAC10.html)
PH (1) PH12020551580A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202009543VA (cg-RX-API-DMAC10.html)
TW (1) TW202003465A (cg-RX-API-DMAC10.html)
WO (1) WO2019191526A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
US10807951B2 (en) 2017-10-13 2020-10-20 The Regents Of The University Of California mTORC1 modulators
EP3860978A1 (en) * 2018-10-03 2021-08-11 The Regents Of The University Of Michigan Small molecule menin inhibitors
TW202126636A (zh) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 作為menin抑制劑之六氫吡啶化合物
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
TW202204334A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
IL328224A (en) * 2023-11-17 2026-07-01 Kura Oncology Inc Methods for treating KIT-positive cancer with a menin inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4767842B2 (ja) * 2003-04-01 2011-09-07 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
US9212180B2 (en) * 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
CN109415337B (zh) * 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
WO2018106818A1 (en) * 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
EP3600313A4 (en) * 2017-03-31 2020-09-23 The Regents of The University of Michigan PIPERIDINES AS COVALENT MENINE INHIBITORS

Also Published As

Publication number Publication date
MX2020010181A (es) 2021-01-15
CN111936465A (zh) 2020-11-13
EP3774731A4 (en) 2021-11-24
BR112020020059A2 (pt) 2021-03-30
JP2021519785A (ja) 2021-08-12
SG11202009543VA (en) 2020-10-29
US20210115018A1 (en) 2021-04-22
IL277659A (en) 2020-11-30
KR20200136958A (ko) 2020-12-08
TW202003465A (zh) 2020-01-16
CA3093454A1 (en) 2019-10-03
WO2019191526A1 (en) 2019-10-03
AU2019243587A1 (en) 2020-09-24
EP3774731A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
PH12019502263A1 (en) Piperidines as covalent menin inhibitors
MX384087B (es) Piperidinas como inhibidores de menina.
PH12020551464A1 (en) Cd73 inhibitors
MX2022000376A (es) Aminopirimidinas como inhibidores de alk.
WO2017176957A8 (en) Mdm2 protein degraders
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
JOP20210105A1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
PH12021550296A1 (en) Substituted indoles and methods of use thereof
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MY196729A (en) Novel compounds
MX371167B (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
SA522431429B1 (ar) Sting مركبات كبيرة الحلقات كمساعِدات وطرق واستخداماتها
MX2018010192A (es) Inhibidores de glucosidasa.
MX2016009011A (es) Compuestos de indazol como inhibidores de cinasa-4 asociada al receptor de interleucina-1 (irak4).
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
TR201903322T4 (tr) Kinaz inhibisyonu için heteroaril bileşikleri.
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
PH12021550374A1 (en) Small molecule menin inhibitors
ZA202307945B (en) Pyridopyrimidinone derivative, preparation method therefor, and use thereof
PH12022551241A1 (en) Egfr inhibitors
PH12020552261A1 (en) Proteasome activity enhancing compounds
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
SA522432710B1 (ar) مركبات حلقية غير متجانسة على هيئة مثبطات نازع تشبّع دلتا-5 وطرق لاستخدامها
PH12021550406A1 (en) Fused ring derivative used as fgfr4 inhibitor
PH12018501132A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer